ANIP at a glance
ANI PHARMACEUTICALS INC (ANIP, SEC CIK 1023024) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ANI PHARMACEUTICALS INC (ANIP) reported revenue of $883.4 million (up 43.8% from FY2024) and net income of $78.3 million. Diluted EPS was $3.32.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding ANI PHARMACEUTICALS INC (ANIP) shares worth $645.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Lalwani Nikhil on November 18, 2026 of 4,082 shares at $71.16 per share.
- In the last 90 days, ANIP insiders reported 0 open-market purchases ($0) and 12 open-market sales ($2.4M) on Form 4, a net sale of $2.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $883.4M
- +43.8% vs prior year
- Insiders · 90 days
- 0 buys · 12 sells
- Net −$2.4M
- 13F holders
- 31 funds
- $645.7M · −3 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: developing, manufacturing, commercializing therapeutics via Rare Disease, Generics, and Brands segments
- Acquired Alimera Sciences on September 16, 2024, adding ILUVIEN® and YUTIQ® products
- Strategic expansion into ophthalmic specialty products through acquisition
- Acquisition introduces new product lines, diversifying portfolio beyond prior scope
Risk Factors
- Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products
- Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions
- Operational/supply chain risk: Reliance on single-source third-party contract manufacturers for Cortrophin Gel and ILUVIEN, risking commercialization delays if noncompliant or unavailable
- Competitive risk: Dependence on Cortrophin Gel, competing with major pharma companies and generics that may have fewer side effects and higher physician acceptance
- Financial/structural risk: 2024 Credit Agreement contains restrictive financial covenants, with potential for accelerated debt repayment and termination if breached
Management Discussion & Analysis
- Total revenue details not provided for FY 2024; Alimera acquisition adds ILUVIEN® and YUTIQ® franchises
- No segment-specific revenue or profit data disclosed
- Sale of Oakville facility for $14.2 million completed in March 2024; no other cash flow or capital allocation details given
- Management highlights growth via ILUVIEN label expansion and Alimera acquisition; no formal guidance or risk outlook stated
AI summary of the ANIP 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New acquisition risk: Egetis offer requires 90% tender acceptance and regulatory clearances, including HSR and foreign-investment approvals
- Most material update: Offer failure could leave significant transaction costs and depress ANI’s share price
- Regulatory risk: Swedish takeover conditions include government approvals and potential restrictions or divestitures
- Financial risk: $676.0 million 364-day bridge facility may require substantial cash servicing and refinancing
- Currency risk: SEK 5.6 billion purchase consideration remains unhedged against Swedish krona appreciation
Management Discussion & Analysis
- Q3 revenue $290.8M, up 27.6% YoY from $227.8M
- Operating margin 18.0% vs 16.1%; net margin 12.0% vs 11.8%
- Best performer: Cortrophin Gel revenue $138.7M, up 36.1%; worst: Brands revenue $10.0M, down 6.5%
- Cash $420.8M vs $285.6M at December 31, 2025; nine-month operating cash flow $198.8M vs $154.9M
- Q3 share repurchases $7.5M; management expects resources sufficient for obligations over next 12 months, with financing needs possible if assumptions change
AI summary of the ANIP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Updated investor presentation published November 16, 2026
- Materials intended for investor and analyst meetings
Item EX-99.1: Item EX-99.1
- 2026 guidance: revenue $1.085B-$1.125B, adjusted EBITDA $290M-$300M, adjusted EPS $9.37-$9.71
- Rare Disease expected to exceed 50% of 2026 revenue, accelerating ANI’s shift away from generics
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary contained in Exhibit 99.1 press release
Item 7.01: Regulation FD Disclosure
- Investor presentation covers third-quarter 2026 results
- Presentation addresses proposed Egetis Therapeutics acquisition
Item EX-99.2: Item EX-99.2
- Q3 2026 revenue $290.8M, up 28% YoY, with adjusted non-GAAP EBITDA $83.3M, up 40%
- Rare Disease revenue $138.7M, up 36% YoY, driven by Cortrophin Gel momentum and gout expansion
Item EX-99.1: Item EX-99.1
- Q3 revenue $290.8M, up 27.6%, with adjusted EBITDA $83.3M, up 39.8%, signaling strong operating momentum
- Cortrophin Gel revenue $138.7M, up 36.1%, but specialty-pharmacy capacity constrained conversion from demand into treated patients
Item EX-99.1: Item EX-99.1
- ANI is preparing a voluntary cash offer for Egetis Therapeutics at SEK 11.25 per share
- Proposed consideration also includes SEK 65,750,817 per convertible and SEK 6.99 per warrant
Item EX-99.2: Item EX-99.2
- Recommended acquisition of Egetis for approximately SEK 5.6B, or $560M, financed with cash on hand and new JPMorgan debt
- Net enterprise value approximately $434M after Egetis’ planned $190.0M PRV sale and related earn-out obligations
Item EX-99.3: Item EX-99.3
- Recommended cash acquisition of Egetis for approximately SEK 5,304 million, expanding ANI’s rare-disease platform with EMCITATE
- Offer price SEK 11.25 per share, premiums of 12.6% to last close, 27.0% to 60-day average and 48.0% to 180-day average
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 points to Item 1.01 for the underlying borrowing or financial obligation details
- Investor impact depends on the referenced agreement’s amount, pricing, maturity, and purpose
Item EX-99.4: Item EX-99.4
- Egetis board unanimously recommends ANI’s SEK 5,304 million cash offer, supporting ANIP’s acquisition of a commercial-stage rare-disease platform
- Consideration: SEK 11.25 per share, SEK 65,750,817 for the EUR 3 million convertible, and SEK 6.99 per warrant
Item 1.01: Entry into a Material Definitive Agreement
- $676 million 364-day senior bridge facility supporting ANI’s proposed cash offer for Egetis Therapeutics
- Facility also earmarked to refinance ANI’s existing term loans and certain Egetis indebtedness
Item 8.01: Other Events
- Recommended cash offer for Egetis: SEK 5.6B, approximately $559.9M total consideration
- Consideration: SEK 11.25 per share, SEK 65,750,817 for the Convertible, and SEK 6.99 per Warrant
AI summaries of ANIP 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ANIP
Don't miss the next ANIP filing
- Alerts as it files. A push when ANIP files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ANIP, by share count.
- Ask anything. An AI agent that reads every ANIP filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lalwani Nikhil | Sell | Nov 18, 2026 | 4,082 | $71.16 |
| Lalwani Nikhil | Sell | Nov 16, 2026 | 1,318 | $71.40 |
| Cook Meredith | Sell | Nov 13, 2026 | 500 | $70.80 |
| CAREY STEPHEN P. | Sell | Oct 29, 2026 | 2,850 | $72.87 |
| Lalwani Nikhil | Sell | Oct 15, 2026 | 5,400 | $71.89 |
| Cook Meredith | Sell | Oct 13, 2026 | 500 | $73.59 |
| CAREY STEPHEN P. | Sell | Sep 29, 2026 | 2,850 | $73.00 |
| Lalwani Nikhil | Sell | Sep 15, 2026 | 5,400 | $71.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $614.4M | $883.4M |
| Operating Income | - | $584K | $111.1M |
| Net Income | $18.8M | -$18.5M | $78.3M |
| Op. Margin | - | 0.1% | 12.6% |
| Net Margin | - | -3.0% | 8.9% |
| Balance Sheet | |||
| Total Assets | $904.4M | $1.3B | $1.4B |
| Equity | - | $403.7M | $540.7M |
| ROE | - | -4.6% | 14.5% |
| Per Share | |||
| EPS | $0.85 | $-1.04 | $3.32 |
| Cash Flow | |||
| Operating CF | - | $64.0M | $185.2M |
| CapEx | $8.9M | $16.2M | $13.8M |
Source: XBRL data in ANI PHARMACEUTICALS INC (ANIP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ANIP share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $645.7M |
| Q2 2026 | 34 | $735.1M |
| Q1 2026 | 32 | $663.3M |
| Q4 2025 | 31 | $688.2M |
| Q3 2025 | 30 | $772.5M |
| Q2 2025 | 29 | $590.4M |
| Q1 2025 | 28 | $498.0M |
| Q4 2024 | 22 | $318.5M |
- BlackRock+197.2K (+7%)
- State Street Corp+119.3K (+14%)
- Dimensional Fund Advisors+105.3K (+17%)
- Vanguard Capital Management LLC+66.5K (+8%)
- Ameriprise Financial+34.2K (+12%)
- Millennium Management−264.1K (-52%)
- JPMorgan Chase & Co−153.9K (-66%)
- D.E. Shaw & Co−65.3K (-37%)
- Raymond James Financial−60.0K (-46%)
- Renaissance Technologies LLC−45.7K (-72%)
- FMR LLC (Fidelity)−36.8K
- Mangrove Partners−9.2K
- Truist Financial−3.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 237 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ANIP filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 4 | Nov 13, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 30, 2026 | - | - | - |
| 4 | Oct 16, 2026 | - | - | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 8-K | Aug 24, 2026 | - | Analysis | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 30, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 14, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ANIP SEC filings: frequently asked questions
Are ANIP insiders buying or selling?
In the last 90 days, ANI PHARMACEUTICALS INC (ANIP) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $2.4 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ANIP stock?
As of September 30, 2026, the largest ANI PHARMACEUTICALS INC (ANIP) holders among the 13F filers tracked by SignalX were BlackRock ($229.3 million), State Street Corp ($69.1 million), Vanguard Capital Management LLC ($65.7 million), Dimensional Fund Advisors ($52.9 million), Vanguard Portfolio Management LLC ($30.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ANIP's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ANI PHARMACEUTICALS INC (ANIP) reported revenue of $883.4 million (up 43.8% from FY2024) and net income of $78.3 million. Diluted EPS was $3.32. The figures come from the XBRL data in the 10-K.
What are the main risks in ANIP's latest 10-K?
In the 10-K filed February 27, 2026, ANI PHARMACEUTICALS INC (ANIP) flagged: Regulatory/legal risk: Compliance with Medicaid Drug Rebate Program risks material penalties due to increased rebate accruals from branded and authorized generic products. Geopolitical/macro risk: 17% of raw materials/API from one domestic supplier in 2025; supply disruption risk from FDA inspections and trade or geopolitical tensions. (AI summary of the Risk Factors section.)
What did ANIP report in its latest 8-K?
ANI PHARMACEUTICALS INC (ANIP) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Updated investor presentation published November 16, 2026.
What are the latest ANIP SEC filings?
ANI PHARMACEUTICALS INC (ANIP) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 18, 2026.
What is ANIP's SEC CIK number?
ANI PHARMACEUTICALS INC (ANIP)'s SEC Central Index Key (CIK) is 1023024. EDGAR lists every ANIP filing under that number.
Ask anything about ANIP
The research agent reads ANIP's filings, financials, insider trades and 13F holders, then answers with sources.